Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 15/7/2019
SIETES contiene 92792 citas

 1 a 20 de 948 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Modin D, Jorgensen ME, Gislason S, Jensen JS, Kober L, Claggett B, Hegde SM, Solomon SD, Torp-Pedersen C, Biering-Sorensen T. Influenza vaccine in heart failure cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. Circulation 2018;139:10 de diciembre. [Ref.ID 102908]
2. Cita con resumen
5. Cita con resumen
Zost SJ, Parkhouse K, Gumina ME, Kim K, Díaz Pérez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains . Proceedings of the National Academy of Sciences of the United States of America 2017:6 de noviembre. [Ref.ID 102123]
6. Cita con resumen
Donahue JG, Kieke BA, King JP, DeStefano F, Mascola MA, Irving SA, Cheetham TC, Glanz JM, Jackson LA, Klein NP, Naleway AL, Weintraub E, Belongia EA. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine 2017;35:5314-22. [Ref.ID 102049]
7. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
8.Enlace a cita original Cita con resumen
Graner S, Svensson T, Beau A-B, Damase-Michel C, Engeland A, Furu K, Hviid A, Haberg SE, Molgaard-Nielsen D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ 2017;356:j629. [Ref.ID 101465]
9. Cita con resumen
Anónimo. Influenza vaccine for 2016-2017. Med Lett Drugs Ther 2016;58:127-30. [Ref.ID 100884]
10. Cita con resumen
Chahal JS, Khan OF, Cooper CL, McPartlan JS, Tsosie JK, Tilley LD, Sidik SM, Lourido S, Langer R, Bavari S, Ploegh HL, Anderson DG. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proceedings of the National Academy of Sciences of the United States of America 2016;113:E4133-42. [Ref.ID 100595]
12. Cita con resumen
Hawkes N. Sixty seconds on . . . Tamiflu. BMJ 2016;353:i3064. [Ref.ID 100384]
13. Cita con resumen
Ludvigsson JF, Ström P, Lundholm C, Cnattingius S, Ekbom A, Órtqvist A, Feltelius N, Granath F, Stephansson O. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. BMJ 2015;351:h5585. [Ref.ID 99695]
14. Cita con resumen
Anónimo. Influenza vaccine for 2015-2016. Med Lett Drugs Ther 2015;57:125-7. [Ref.ID 99652]
15. Cita con resumen
Anónimo. Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther 2015;57:17-9. [Ref.ID 98855]
16. Cita con resumen
Young K. Favipiravir shows some promise in early Ebola study. Journal Watch 2015:1. [Ref.ID 98771]
17. Cita con resumen
Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015;385:1729-37. [Ref.ID 98765]
18. Cita con resumen
Anónimo. Early estimates of seasonal influenza vaccine effectiveness — United States, January 2015. Morbidity and Mortality Weekly Report 2015;64:10-5. [Ref.ID 98711]
19. Cita con resumen
Anónimo. FDA approves Rapivab to treat flu infection. U.S. Food and Drug Administration 2014:1. [Ref.ID 98394]
20. Cita con resumen
Sofair A, Chavey WE. 2014-15 flu vaccine not a perfect match to circulating viruses. Physician's First Watch 2014:5 de diciembre. [Ref.ID 98348]
Seleccionar todas
 1 a 20 de 948 siguiente >>